Literature DB >> 33811300

Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.

Eun Yong Chung1, Hye Jin Cha2, Hyun Kyu Min3, Jaesuk Yun4.   

Abstract

Over the last decade, new psychoactive substances (NPS) have continuously been the focus of the international society since their emergence on the illicit drug market. NPS can be classified into six groups including; synthetic cannabinoid receptor agonists (SCRAs), stimulants, opioids, dissociatives, sedatives/hypnotics, and classic hallucinogens with psychoactive effects. These are sold as "herbal incense," "bath salts," "legal highs," and "research chemicals". They can be synthesized easily with slight changes in the chemical moieties of known psychoactive substances. NPS are sold worldwide via on- and off-line markets without proper scientific evaluation regarding their safety or harmfulness. Abuse of NPS poses a serious public health issue, and systematic studies on their adverse effects are lacking. Therefore, it would be meaningful to collect currently available data in order to understand NPS and to establish viable solutions to cope with the various health issues related to them. In this article, we reviewed the general pharmacological characteristics, recent findings, and adverse effects of representative NPS; SCRAs. SCRAs are known as the most commonly abused NPS. Most SCRAs, cannabinoid receptor 1 and cannabinoid receptor 2 agonists, are often associated with severe toxicities, including cardiotoxicity, immunotoxicity, and even death, unlike natural cannabinoid Δ9-Tetrahydrocannabinol.

Entities:  

Keywords:  Adverse effects; New psychoactive substances; Pharmacology; Synthetic cannabinoid receptor agonists; Toxicity

Year:  2021        PMID: 33811300     DOI: 10.1007/s12272-021-01326-6

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  72 in total

1.  'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs?

Authors:  Volker Auwärter; Sebastian Dresen; Wolfgang Weinmann; Michael Müller; Michael Pütz; Nerea Ferreirós
Journal:  J Mass Spectrom       Date:  2009-05       Impact factor: 1.982

2.  A new designer drug 5F-ADB activates midbrain dopaminergic neurons but not serotonergic neurons.

Authors:  Nozomi Asaoka; Hiroyuki Kawai; Naoya Nishitani; Haruko Kinoshita; Norihiro Shibui; Kazuki Nagayasu; Hisashi Shirakawa; Shuji Kaneko
Journal:  J Toxicol Sci       Date:  2016       Impact factor: 2.196

Review 3.  The effects of Δ9-tetrahydrocannabinol on the dopamine system.

Authors:  Michael A P Bloomfield; Abhishekh H Ashok; Nora D Volkow; Oliver D Howes
Journal:  Nature       Date:  2016-11-17       Impact factor: 49.962

4.  Inhibitory effect of synthetic cannabinoids on CYP1A activity in mouse liver microsomes.

Authors:  Takashi Ashino; Kanae Hakukawa; Yuka Itoh; Satoshi Numazawa
Journal:  J Toxicol Sci       Date:  2014       Impact factor: 2.196

Review 5.  Marijuana as a trigger of cardiovascular events: speculation or scientific certainty?

Authors:  Arash Aryana; Mark A Williams
Journal:  Int J Cardiol       Date:  2006-09-26       Impact factor: 4.164

6.  AKI associated with synthetic cannabinoids: a case series.

Authors:  Gautam Kantilal Bhanushali; Gaurav Jain; Huma Fatima; Leah J Leisch; Denyse Thornley-Brown
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-14       Impact factor: 8.237

7.  Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.

Authors:  Giovanni Appendino; Simon Gibbons; Anna Giana; Alberto Pagani; Gianpaolo Grassi; Michael Stavri; Eileen Smith; M Mukhlesur Rahman
Journal:  J Nat Prod       Date:  2008-08-06       Impact factor: 4.050

Review 8.  Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis.

Authors:  Mark Asbridge; Jill A Hayden; Jennifer L Cartwright
Journal:  BMJ       Date:  2012-02-09

9.  Synthetic cannabinoid induced acute respiratory depression: Case series and literature review.

Authors:  Mark Henry Alon; Margaret Olibrice Saint-Fleur
Journal:  Respir Med Case Rep       Date:  2017-07-29

Review 10.  Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings.

Authors:  Albert Batalla; Sagnik Bhattacharyya; Murat Yücel; Paolo Fusar-Poli; Jose Alexandre Crippa; Santiago Nogué; Marta Torrens; Jesús Pujol; Magí Farré; Rocio Martin-Santos
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

View more
  2 in total

Review 1.  Why Do Marijuana and Synthetic Cannabimimetics Induce Acute Myocardial Infarction in Healthy Young People?

Authors:  Jolanta Weresa; Anna Pędzińska-Betiuk; Krzysztof Mińczuk; Barbara Malinowska; Eberhard Schlicker
Journal:  Cells       Date:  2022-03-28       Impact factor: 6.600

Review 2.  Acute Kidney Injury (AKI) in Young Synthetic Cannabinoids Abusers.

Authors:  Stefano D'Errico; Martina Zanon; Davide Radaelli; Monica Concato; Martina Padovano; Matteo Scopetti; Paola Frati; Vittorio Fineschi
Journal:  Biomedicines       Date:  2022-08-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.